Pharmaceuticals

Next Generation Antibody Drug Market Growth Expected To Reach $5.66 Billion By 2030 At 5.8% CAGR

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Next Generation Antibody Drug Market Over The 2026–2030 Period?

The next generation antibody drug market size has undergone rapid expansion in recent years. It is forecast to increase from $16.4 billion in 2025 to $18.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.4%. This historical growth can be attributed to various factors such as the success of monoclonal antibody therapies, the rising prevalence of cancer, advancements in antibody engineering, increased biologics r&d investment, and regulatory approvals of antibody drugs.

The next generation antibody drug market size is projected to experience substantial growth in the coming years, with expectations to reach $33.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.4%. This expansion during the forecast period can be attributed to factors such as increasing adoption of precision medicine, a heightened demand for targeted biologics, advancements in conjugation technologies, the broadening scope of autoimmune disease treatments, and a rising number of oncology drug pipelines. Key trends identified for this period include the accelerated development of bispecific antibodies, increasing utilization of antibody-drug conjugates, a growing emphasis on precision targeted therapies, the expansion of antibody applications beyond oncology, and a surge in clinical trials for advanced antibody platforms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp

What Major Factors Are Driving The Next Generation Antibody Drug Market Forward?

The escalating emphasis on personalized medicine is projected to stimulate the growth of the next-generation antibody-drug market in the foreseeable future. Personalized medicine defines a medical methodology that tailors treatment and healthcare strategies to specific patients, considering their genetic, environmental, and lifestyle elements to deliver more effective and precise therapies. This approach is gaining prominence due to advancements in genomic sequencing, which permit more accurate diagnoses and targeted treatment plans. Next-generation antibody drugs support the amplified focus on personalized medicine by enabling the creation of targeted therapies specifically customized to individual patients’ genetic profiles and disease characteristics, thereby enhancing efficacy and reducing adverse effects. For instance, in February 2024, as per the Personalized Medicine Coalition, a US-based organization promoting the adoption of personalized medicine, in 2023, the United States Food and Drug Administration (FDA) gave approval to 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Hence, the increasing focus on personalized medicine drives the next-generation antibody drug market.

What Segment Categories Shape The Next Generation Antibody Drug Market Segment Landscape?

The next generation antibody drug market covered in this report is segmented –

1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies

3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration

4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications

5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies

2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies

3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates

What Trends Are Shaping The Future Of The Next Generation Antibody Drug Market?

Major companies operating in the next generation antibody drug market are prioritizing the development of innovative solutions, such as antibody-drug conjugates, to advance targeted cancer therapies, enhance therapeutic efficacy, and mitigate systemic toxicity. An antibody-drug conjugate (ADC) is a specialized cancer treatment that connects a monoclonal antibody with a cytotoxic drug via a linker, ensuring the selective delivery of the drug to tumor cells while minimizing damage to healthy tissue. As an illustration, in January 2024, BioNTech SE, a Germany-based biotechnology company, formed a partnership with Duality Biologics (Suzhou) Co. Ltd., a China-based pharmaceutical company, and subsequently secured a Fast Track designation from the U.S. Food and Drug Administration (FDA) for their next-generation antibody-drug conjugate (ADC) candidate, BNT325/DB-1305, designed for the treatment of platinum-resistant ovarian cancer. This drug leverages DualityBio’s cutting-edge DITAC (Duality Immune Toxin Antibody Conjugates) platform, which integrates a highly potent cytotoxic payload with a monoclonal antibody, enabling precise treatment delivery directly to cancer cells. The standout advantage of BNT325/DB-1305 is its capability to accurately target cancer cells while simultaneously reducing harm to healthy tissues, thereby significantly improving treatment efficacy and lessening side effects.

Who Are The Companies Operating Across The Next Generation Antibody Drug Market Value Chain?

Major companies operating in the next generation antibody drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited, Actinium Pharmaceuticals Inc.

Get The Full Next Generation Antibody Drug Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report

Which Region Is The Top Contributor To The Next Generation Antibody Drug Market By Share?

North America was the largest region in the next generation antibody drug market in 2025. The regions covered in the next generation antibody drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Next Generation Antibody Drug Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report

Browse Through More Reports Similar to the Global Next Generation Antibody Drug Market 2026, By The Business Research Company

Next Generation Antibody Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Antibody Drug Conjugates Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795